Literature DB >> 15266089

Molecularly targeted therapy: have the floodgates opened?

Brian J Druker1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15266089     DOI： 10.1634/theoncologist.9-4-357

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  14 in total

Review 1.  Chasing phosphohistidine, an elusive sibling in the phosphoamino acid family.

Authors:  Jung-Min Kee; Tom W Muir
Journal:  ACS Chem Biol       Date:  2011-12-09       Impact factor: 5.100

2.  Molecular basis for specificity in the druggable kinome: sequence-based analysis.

Authors:  Jianping Chen; Xi Zhang; Ariel Fernández
Journal:  Bioinformatics       Date:  2007-01-25       Impact factor: 6.937

3.  Development of stable phosphohistidine analogues.

Authors:  Jung-Min Kee; Bryeanna Villani; Laura R Carpenter; Tom W Muir
Journal:  J Am Chem Soc       Date:  2010-10-20       Impact factor: 15.419

Review 4.  Kinase packing defects as drug targets.

Authors:  Alejandro Crespo; Ariel Fernández
Journal:  Drug Discov Today       Date:  2007-10-30       Impact factor: 7.851

Review 5.  Nanotechnology and cancer.

Authors:  James R Heath; Mark E Davis
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

Review 6.  Targeted therapies for gynecologic malignancies.

Authors:  Johnny Hyde; D Scott McMeekin
Journal:  Curr Treat Options Oncol       Date:  2005-03

7.  c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.

Authors:  Pablo Vivas-Mejia; Juliana Maria Benito; Ariel Fernandez; Hee-Dong Han; Lingegowda Mangala; Cristian Rodriguez-Aguayo; Arturo Chavez-Reyes; Yvonne G Lin; Mark S Carey; Alpa M Nick; Rebecca L Stone; Hye Sun Kim; Francois-Xavier Claret; William Bornmann; Bryan T J Hennessy; Angela Sanguino; Zhengong Peng; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

Review 8.  Advances in development of new tools for the study of phosphohistidine.

Authors:  Mehul V Makwana; Richmond Muimo; Richard Fw Jackson
Journal:  Lab Invest       Date:  2017-12-04       Impact factor: 5.662

9.  Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.

Authors:  Suman Kundu; Keke Fan; Mingli Cao; Daniel J Lindner; Zhizhaung Joe Zhao; Ernest Borden; Taolin Yi
Journal:  J Immunol       Date:  2010-04-26       Impact factor: 5.422

10.  Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.

Authors:  Atul B Shinagare; Jyothi P Jagannathan; Vikram Kurra; Trinity Urban; Judith Manola; Edwin Choy; George D Demetri; Suzanne George; Nikhil H Ramaiya
Journal:  Eur J Cancer       Date:  2014-01-02       Impact factor: 9.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.